Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ: CADL )

8.750 +0.810 (+10.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
Via Stocktwits
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Major Indexes Falter; Dow Drops Over 550 Points
The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
How Is The Market Feeling About Candel Therapeutics?
Via Benzinga
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 
Via Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments. 
Via Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
What's Going On With Candel Therapeutics Shares Friday?
Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants. 
Via Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Candel Therapeutics Shares Are Up Today: What's Going On?
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its... 
Via Benzinga
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high. 
Via Benzinga
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
Via Benzinga
Exposures Fossil Fuels
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Via Benzinga
Topics Economy
Exposures Interest Rates
Candel Therapeutics Stock Surges Over 100% - Here's Why
Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency. 
Via Benzinga
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
The company is hoping to eventually launch the first major new treatment for localized prostate cancer in over 20 years. 
Via Investor's Business Daily
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
Candel Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments 
Via News Direct
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
Why BioRestorative Therapies Stock Is Moving Higher Thursday
BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic... 
Via Benzinga
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
--News Direct-- 
Via News Direct
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer 
Via News Direct
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS